Treatment Initiation and Selection in Newly Diagnosed CLL

Content Outline

The Patient Is at the Center of First-Line CLL Treatment Decisions

Understanding CLL Risk Stratification

Alliance A041202 Ibrutinib or Ibrutinib-Rituximab for Older Patients With CLL

Ibrutinib-Containing Therapy PFS in Older Patients

Alliance Study Grade ≥ 3 Adverse Events of Interest

E1912 Ibrutinib-Rituximab in Younger Patients

Can We Predict Who Will Experience Long-Term Remission?

Ibrutinib Toxicity, Young vs Old

Can Thoughtful Treatment Sequencing Reduce TLS Associated With Venetoclax?

Ibrutinib-Venetoclax Short-Term Follow-Up in Previously Untreated CLL

Careful Treatment Sequencing May Reduce Risk of TLS

3-Year Follow-Up With Acalabrutinib

iLLUMINATE Study Design

Ibrutinib-Obinutuzumab Activity in Previously Untreated CLL

iLLUMINATE Grade ≥ 3 Toxicities of Interest

Let's Consider a Patient

Deciding When to Use Ibrutinib in Non-Del(17p) Previously Untreated CLL

Does the Patient Want Time-Limited or Continuous Therapy?

When to Consider Ibrutinib-Free First-Line Therapy

More Informed = Better Prepared to Decide

Key Considerations for First-Line Treatment Selection

Molecular Testing Remains an Unmet Need

Helping Patients Transition From Watchful Waiting to Definitive Therapy

Moving Beyond Chemotherapy Pros and Cons

Fitting Therapy to Patients

Key Takeaways

Abbreviations

Abbreviations (cont)